Skyscrapers Above Times Square at Dawn
PUBLICATIONS
COVID-19: As we Emerge Into a “New Normal” Balance Your Risks

September 16, 2020

When lockdown began in March 2020, we believed it was temporary and that, at a point, life would go back to normal. In some areas, such as western Europe and the northeastern United States, the peak of COVID-19 has passed, but there is no treatment, there is no vaccine and the virus lurks around every corner.

The Economic Value of Rapid AST in Reducing Length of Stay of Septic Patients

August 14, 2020

To construct an economic model to estimate the potential length-of-stay cost savings for hospitals which replace conventional antibiotic susceptibility testing (AST) with rapid AST for the sepsis patient population. We used a wide range of academic studies from the medical andeconomics literature. Relevant studies were identified and weighted based on study methodological rigor, year of publication and geographic proximity of study population.

Weighing the Economics, Public Health Benefits of Sheltering in Place

August 12, 2020

Imagine trying to hold your breath. Some of us can hold it only for a few moments, others for a bit longer. Now imagine trying to hold your breath as someone starts taking the air out of your lungs. The impulse to breathe becomes much stronger.

Medicare For All 2020

September 2019

Healthcare reform has historically been an incre- mental process in the United States. What began nearly 100 years ago as a political slogan as part of President Teddy Roosevelt’s unsuccessful run for a third term in 1912 evolved into a program proposed to Congress by President Harry S. Truman in 1945.

A Financial Analysis of New York City Start-up Health Plans and Reasons for Their Losses

November 12, 2018

Using New York City as an example, this research explores reasons for the consistently poor financial performance of three start-up health plans (Health Republic, CareConnect, and Oscar) while other health plans have performed relatively well in the same market.

An Economic Evaluation of American Patients First –The Trump Administration’s Strategy to Lower Drug Prices

July 2018

Prescribing pharmaceuticals for patients is one major way that internists heal patients, making the cost of those drugs—purchased through mail-order, healthplans, or directly from pharmacies—a growing issue in primary care. Since candidate Donald Trump first departed from the Republican Party line by promising to reduce drug prices, the health policy world wondered how. 

The Potential Premium Impact Of An Essential Health Benefits Benchmark Change In Four States

January 4, 2018

One major goal of the Affordable Care Act (ACA) was the creation of a functioning individual market for health insurance that protected consumers and offered affordable insurance. The ACA’s consumer protections included premium protections, such as the elimination of ratings based on pre-existing conditions, as well as benefit protections like the elimination of annual limits. In addition, the ACA guaranteed that a set of "essential health benefits" (EHB) would be included in every health plan in the individual and small group markets.

Premium Rate Variation In Exchanges Is An Eye Opener

August 7, 2013

Like a burlesque strip tease for health policy wonks, the slow motion unveiling of premiums for state health insurance exchanges has generated a lot of attention, unease, and, yes, excitement.  The 2014 premiums, the first for Obamacare’s centerpiece feature of health insurance marketplaces, represent nothing short of a referendum on the “affordable” in the Affordable Care Act.

Nurse Labor Effects of Residency Work Hours Limits

February 2009

An 80-hour work week was not particularly novel when it was instituted by the ACGME in 2003.

Costs and Benefits of Increased Drug Use Due to Direct-To-Consumer Advertising: The Case of Depression

June 2007

There has been broad debate in the US as to whether direct-to-consumer advertising (DTCA) should continue, or be essentially prohibited as in Europe. Underlying this policy debate is the eco- nomic question: what benefits and costs are attribu- table to the billions spent on DTCA in the US each year ($US3.2 billion in 2003)?[1] Proponents of DTCA argue that it provides valuable information to the public about conditions and treatments, without which many treatable conditions would go untreated.

Kelly Goes Back to School:

More Science on Coronavirus

by Lauren Block MD MPH and Adam Block PhD

Illustrated by Alex Brissenden

 
  • Facebook
  • LinkedIn
  • Instagram
  • Twitter

© 2020 Copyright CHARM ECONOMICS, LLC. All Rights Reserved.